Success – One customer at a time.

Accera

Accera, Inc. is a privately held, commercial-stage biotechnology company that developed and now markets Axona® in the US. Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer’s disease.

Actelion

Actelion Ltd is a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland. It’s first drug, Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension and is marketed through its own subsidiaries in key markets worldwide including the USA, EU, Japan, Canada, Australia and Switzerland. Founded in 1997, Actelion is a leading player in innovative science related to the endothelium and has over 2,500 employees focused on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange as part of the Swiss blue-chip index SMI.

Affymax

Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. A New Drug Application for Affymax’s product candidate, peginesatide, for the treatment of anemia in adult chronic kidney disease patients on dialysis is under review by the U.S. Food and Drug Administration. For additional information, please visit www.affymax.com.

Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products.

Amgen

Amgen is a leading human therapeutics company in the biotechnology industry. For more than 25 years, Amgen has tapped the power of scientific discovery and innovation to advance the practice of medicine.

Astellas

Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organization is committed to becoming a global company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market.

AstraZeneca

AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. They discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory and inflammation.

Bayer/Intendis

Bayer HealthCare’s Dermatology Unit is a specialized global pharmaceutical company focused solely in dermatology. It is headquartered in Berlin, and was founded in 2005 as a subsidiary of Schering AG, Germany. Today, Dermatology is part of the Bayer Group with commercial operations around the globe. The affiliate in the United States is headquartered in Morristown, NJ, and currently offers the following products: Finacea® (azelaic acid) Gel, 15% and Desonate® (desonide) Gel 0.05%.

Becton, Dickinson & Co (BD)

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Biocodex

Biocodex is an independent, family-owned French pharmaceutical company founded in 1953 by Michel Hublot and Francois Vallet. They specialize in gastroenterology, neurology and psychiatry, pain treatment and treatment of degenerative osteoarthritis.

Daiichi-Sankyo

Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly €7.3 billion, Daiichi Sankyo is one of the world’s 20 leading pharmaceutical companies.

Dyax

Dyax’s mission is to discover, develop and commercialize innovative biopharmaceuticals for unmet medical needs while delivering outstanding value to patients and stockholders.

At the core of  their success is their powerful and proprietary drug discovery technology, phage display. This technology provides them a unique advantage of being able to identify and develop their own clinical leads to fuel their internal pipeline. They also leverage phage display into licenses and collaborations with companies and researchers interested in furthering their own pipelines.

Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers — through medicines and information — for some of the world’s most urgent medical needs.

Grunenthal

As an independent, family-owned corporation, we are passionate about being the preferred partner in pain management worldwide, thus contributing to people’s health and quality of life.

We are focused on innovation and strive to be leaders in providing solutions for the treatment of moderate to severe pain.

This leadership is built on our internal skills and competencies, and is complemented by collaboration with external partners.

Horizon Pharma

Horizon Pharma, Inc. is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.

Human Genome Sciences

Human Genome Sciences (HGS) is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. With a commitment to scientific rigor and the pursuit of excellence, HGS is working systematically to achieve breakthrough results one careful step at a time.

InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases. In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®. InterMune’s research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.

Iroko Cardio

Iroko Cardio is a privately held pharmaceutical company located in Geneva, Switzerland, and Philadelphia, USA. In close collaboration with regional distribution partners, Iroko produces and promotes Aggrastat/Agrastat® worldwide with the exception of the USA. Iroko Cardio aims to contribute to the reduction of major adverse cardiac events in the regions it serves.

Ironwood

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood’s GC‐C agonist, is an investigational drug for the treatment of irritable bowel syndrome with constipation (IBS‐C) and chronic constipation (CC). The efficacy portion of linaclotide’s development program has been completed and supports the recently submitted NDA submission for both indications, as well as the MAA submission in Europe for the IBS‐C indication. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass.

ISTA

ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), is a rapidly growing pharmaceutical company with the third largest branded prescription eye care business in the United States and an emerging allergy drug franchise. The Company’s marketed products and development pipeline candidates are intended to address key segments of the $6.5 billion ophthalmic pharmaceutical market and the $2.5 billion nasal allergy market.

Kadmon

Kadmon is a global biopharmaceutical company built on a 21st-century paradigm for the translation of innovative science into treatment. The company currently offers products and services for the treatment and management of hepatitis C. Kadmon is pioneering medicines in oncology, infectious diseases, immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. Kadmon’s strategy breaks from the costly, time-consuming and inefficient drug development models of the past by leveraging its growing, specialist-driven commercial platform to advance a pipeline of novel small molecules and biologics. By challenging how treatments for serious diseases are developed today, Kadmon is developing the cures of tomorrow.

Kadmon Corporation, LLC is headquartered in New York City with operations in Warrendale, PA and Boston, MA.

Kythera

KYTHERA Biopharmaceuticals, Inc. is a privately-held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market.

The aesthetic market is characterized by an aging population, increasing discretionary income and an evolution of patient preference towards care that focuses on quality of life.

Leo Pharma

LEO Pharma is a leading, global pharma company specializing in dermatology and critical care. For more than a century, their products have improved the quality of millions of people’s lives around the world. Headquartered in Denmark, Leo has employees in 58 countries and their products are sold in more than 100 countries.

MAP Pharma

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The New Drug Application for LEVADEX is currently under review by the U.S. Food and Drug Administration. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Merz Pharma GmbH & KGaA

Merz Pharmaceuticals, LLC is a part of the Merz Group of Companies and was established in 1995 to develop and commercialize products for the Merz Group. Areas of therapeutic focus include Neurology, Dermatology, and Podiatry along with the #1 non-prescription product for scars, Mederma®, and Mederma® Stretch Marks Therapy.

Millennium Pharmaceuticals

Millennium Pharmaceuticals, Inc., The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product and has a robust clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation.

Mundipharma

Mundipharma and its independent associated companies are committed to improving the health and quality of life of people everywhere. Over the last 50 years, Mundipharma has become  a leader in the area of pain management, developing new drugs and patented formulations to relieve chronic pain for patients and to help them improve their lives. Mundipharma also has a strong presence in onco-hematology treatments to help transform the lives of even more patients.

Novartis

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products.

Noven Therapeautics

Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, its customers and its industry partners. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., and serves as Hisamitsu’s U.S. growth platform in prescription pharmaceuticals.

Novogyne

Novogyne Pharmaceuticals is a joint venture between Novartis Pharmaceuticals Corporation and Noven Pharmaceuticals, Inc. Since May 1998, Novogyne has been offering pharmaceutical products that enable physicians to better serve the medical needs of mature women. Novogyne’s products include Vivelle-Dot® (estradiol transdermal system), the #1 prescribed estrogen patch and the smallest estrogen patch available, and CombiPatch® (estradiol/norethindrone acetate transdermal system). With these advanced patches, Novogyne was the first company in the United States offering transdermal systems for both the estrogen-only and combination estrogen/progestin markets.

OSI Pharmaceuticals

OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by discovering, developing and commercializing high-quality, novel and differentiated targeted medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity.

PDI

PDI provides commercialization services for established and emerging biopharmaceutical companies. The Company is dedicated to maximizing the return on investment for its clients by providing strategic flexibility, sales, marketing and commercialization expertise.

Pharco

Pharco Pharma NV/SA is a publicly listed company (PHAR:BB) specializing in prescribed food supplements. Since 2001, Pharco has developed and marketed products in Belgium and a number of other European countries.

Proton Pharma

Proton Pharma is a new Greek pharmaceutical company which aims to offer valuable therapeutic options of high quality and safety at the lowest possible cost. Additionally, Proton Pharma in collaboration with international research institutes develops new therapeutic approaches to diseases with unmet medical needs.

Publicis Touchpoint Solutions

Publicis Touchpoint Solutions provides a comprehensive array of multichannel message delivery solutions to the life sciences industry. Publicis Touchpoint Solutions provides the human touch to precision multichannel messaging delivered at the right time and through the right channels to achieve maximum impact.

QLT

QLT is dedicated to developing innovative ocular products. The company intends to commercialize these products themselves in North America and strives to deliver meaningful return to their shareholders as their current development products reach the market over the next 10 years. QLT seeks to become a top-tier ophthalmology company based on their development innovation, strong commercial presence and focus on ocular drugs and devices.

Quintiles

Quintiles is the only fully integrated bio and pharmaceutical services provider offering clinical, commercial, consulting and capital solutions. The company’s 23,000 employees, in more than 50 countries, have helped develop or commercialize all of the top 30 best-selling drugs.

Rottapharm Hellas SA

In 2000, with the takeover of the Saugella and Babygella brands, Rottapharm made its entrance into the parapharmaceutical sector and in a short time, it has reached a leadership position within the market of personal hygiene products sold in pharmacies. At the same time, the Group has started to work within the nutraceutic sector by developing products based on natural ingredients for the treatment of menopause symptoms (Estromineral Line), dyslipidemia (Armolipid Line) as well as inflammations (Fortilase Line).

Today, Rottapharm | Madaus is present in approximately 85 Countries worldwide, with more than 2,000 employees. Its headquarters are in Monza where the Group’s research and development centre is also situated. In 2010, the Group has achieved a turnover of approximately 600 million Euro

Savient

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University (“Duke”) and Mountain View Pharmaceuticals, Inc. (“MVP”). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

Shire

As one of the world’s leading specialty biopharmaceutical companies, Shire has emerged as a company fully focused on a single purpose: to enable people with life-altering conditions to lead better lives.

Shire is a global company with offices in the major pharmaceutical markets. Its UK offices are in Basingstoke and its US offices are in Wayne, Pennsylvania.

Stallergenes

Stallergenes is a European biopharmaceutical laboratory specializing in treatments by allergenic immunotherapy for the prevention and treatment of allergy-related respiratory conditions such as severe rhino conjunctivitis, rhinitis and allergic asthma. A pioneer and a leader in immunotherapy treatments by sublingual administration, Stallergenes dedicates nearly 20% (gross) of its sales to its Research and Development activities which are primarily directed at developing a new therapeutic range: sublingual immunotherapy tablets. Stallergenes realized 2010 sales of € 216 million, with over 500,000 patients treated with Stallergenes products.

Strativa

Strativa Pharmaceuticals is the proprietary products division of Par Pharmaceutical Companies, Inc. They are bringing to market novel, proprietary products by applying innovative technologies, reformulation techniques and delivery systems to enhance their performance.

Sucampo

Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development.

Sunovion

Sunovion is a leading pharmaceutical company dedicated to discovering, developing and bringing to market therapeutic products that advance the science of medicine to improve the lives of patients, their families and communities by specializing in treatments that help people challenged by disorders of the central nervous system and respiratory ailments.

Supernus

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company’s extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization, then as a U.S. subsidiary of Shire plc and, upon its acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy and ADHD including ADHD patients with impulsive aggression.

Théa

Laboratoires Théa was founded by Henri CHIBERT, a fourth-generation member of a French ophthalmological dynasty, born in the nineteenth century. Set up in 1994 from an R&D start-up company, Théa has played an important role in the latest pharmacological advances and in less than 10 years has risen to become the leading independent eye-care group in Europe. Henri and Jean-Fréderic CHIBERT (a fifth generation member of the dynasty) have presided over the group since 2008.

Present in over 65 countries, particularly in Europe, North and Sub Saharan Africa, South America and the Middle East, Théa is proud of its roots in the Auvergne region of France. Its head office is based in the capital of the Auvergne (Clermont-Ferrand) and is at the heart of a network comprising almost 600 employees worldwide.

Unigene

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and recombinant manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies and proprietary, high-yield, scalable and robust E. coli-based manufacturing technologies, including peptide amidation.

Upsher Smith Labs

Upsher-Smith Laboratories, Inc., founded in 1919, is a rapidly growing, privately held pharmaceutical company that develops, manufactures, and markets prescription and consumer products. Upsher-Smith’s product portfolio focuses in the areas of women’s health, dermatology, cardiology, and CNS diseases. The company’s focus is growing a CNS pipeline for diseases with significant unmet need, including epilepsy and Parkinson’s disease. To expand its CNS pipeline, Upsher-Smith seeks alliances and co-development programs, pursues licensing and acquisitions, and leverages its core competency in formulation development.